10 min listen
Timothy Ko, Entheon Biomedical
ratings:
Length:
27 minutes
Released:
May 11, 2021
Format:
Podcast episode
Description
In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) a biotechnology company focused on developing psychedelic medicines to treat addiction.In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound, DMT, to address the global addiction crisis, and how they are using genetics to develop more effective personalized treatment regimens for patients.*To learn more about the company featured in this episode and the work they’re doing, visit their website: EntheonBiomedical.com*Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing. Visit our Website: PsychedelicSpotlight.comSubscribe to our YouTube ChannelFollow us on InstagramLike us on FacebookFollow us on Twitter*This episode was recorded on May 5, 2021.
Released:
May 11, 2021
Format:
Podcast episode
Titles in the series (100)
Ronan Levy, Field Trip Health: Global Trac Solutions, Inc., CEO, David Flores, sits down with Field Trip Health, Founder & Executive Chairman, Ronan Levy. by Psychedelic Spotlight Podcast